دورية أكاديمية
Mucosal administration of a live attenuated recombinant COVID-19 vaccine protects nonhuman primates from SARS-CoV-2
| العنوان: | Mucosal administration of a live attenuated recombinant COVID-19 vaccine protects nonhuman primates from SARS-CoV-2 |
|---|---|
| المؤلفون: | Mariana F. Tioni, Robert Jordan, Angie Silva Pena, Aditya Garg, Danlu Wu, Shannon I. Phan, Christopher M. Weiss, Xing Cheng, Jack Greenhouse, Tatyana Orekov, Daniel Valentin, Swagata Kar, Laurent Pessaint, Hanne Andersen, Christopher C. Stobart, Melissa H. Bloodworth, R. Stokes Peebles, Yang Liu, Xuping Xie, Pei-Yong Shi, Martin L. Moore, Roderick S. Tang |
| المصدر: | npj Vaccines, Vol 7, Iss 1, Pp 1-13 (2022) |
| بيانات النشر: | Nature Portfolio, 2022. |
| سنة النشر: | 2022 |
| المجموعة: | LCC:Immunologic diseases. Allergy LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| مصطلحات موضوعية: | Immunologic diseases. Allergy, RC581-607, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| الوصف: | Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the COVID-19 global pandemic. SARS-CoV-2 is an enveloped RNA virus that relies on its trimeric surface glycoprotein spike for entry into host cells. Here we describe the COVID-19 vaccine candidate MV-014-212, a live, attenuated, recombinant human respiratory syncytial virus expressing a chimeric SARS-CoV-2 spike as the only viral envelope protein. MV-014-212 was attenuated and immunogenic in African green monkeys (AGMs). One mucosal administration of MV-014-212 in AGMs protected against SARS-CoV-2 challenge, reducing by more than 200-fold the peak shedding of SARS-CoV-2 in the nose. MV-014-212 elicited mucosal immunoglobulin A in the nose and neutralizing antibodies in serum that exhibited cross-neutralization against virus variants of concern Alpha, Beta, and Delta. Intranasally delivered, live attenuated vaccines such as MV-014-212 entail low-cost manufacturing suitable for global deployment. MV-014-212 is currently in Phase 1 clinical trials as an intranasal COVID-19 vaccine. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2059-0105 |
| Relation: | https://doaj.org/toc/2059-0105 |
| DOI: | 10.1038/s41541-022-00509-6 |
| URL الوصول: | https://doaj.org/article/87b82e0844a44499a2c4b6faecce72a2 |
| رقم الأكسشن: | edsdoj.87b82e0844a44499a2c4b6faecce72a2 |
| قاعدة البيانات: | Directory of Open Access Journals |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 20590105 |
|---|---|
| DOI: | 10.1038/s41541-022-00509-6 |